Kestra Medical Technologies (KMTS) EBITDA Margin (2024 - 2026)

Kestra Medical Technologies (KMTS) has reported EBITDA Margin for 3 consecutive years, with 137.38% the latest figure, recorded in Q2 2026.

• On a quarterly basis, EBITDA Margin rose 14238.0% year-over-year to 137.38% in Q2 2026; TTM through Apr 2026 was 141.65%, a 3620.0% increase from a year earlier, with the FY2026 full-year figure at 141.64%, up 3620.0% from the prior year.
• EBITDA Margin was 137.38% for Q2 2026 at Kestra Medical Technologies, up from 141.6% in the prior quarter.
• Over five years, EBITDA Margin peaked at 130.07% in Q4 2024 and troughed at 279.77% in Q2 2025.
• A 3-year average of 170.27% and a median of 142.9% in 2024 frame the typical range for EBITDA Margin.
• Across the five-year window, EBITDA Margin plunged 7737 bps in 2025 and surged 14238 bps in 2026, its largest moves.
• Over 3 years, EBITDA Margin stood at 130.07% in 2024, then fell by 8 bps to 140.73% in 2025, then grew by 2 bps to 137.38% in 2026.
• The last three EBITDA Margin figures came in at 137.38% (Q2 2026), 141.6% (Q1 2026), and 140.73% (Q4 2025), per Business Quant data.